Details

Autor(en) / Beteiligte

• Rampal, P.
• Raillat, A.
• Viteau, J.-M.
• Slama, J.-L.
• Lavignolle, A.
• Bedenne, L.
• Veyres, B.
• Toulet, J.
• Vray, M.
• Prunieras, F.

Titel

Rioprostil and Ranitidine in the Prevention of Duodenal Ulcer Relapse

Ist Teil von

• Scandinavian journal of gastroenterology, 1989, Vol.24 (S164), p.146-151

Ort / Verlag

Informa UK Ltd

Erscheinungsjahr

1989

Quelle

Taylor & Francis Journals Auto-Holdings Collection

Beschreibungen/Notizen

• Rampal P, Raillat A, Viteau J-M, Slama J-L, Lavignolle A, Bedenne L, Veyres B, Toulet J, Vray M, Prunieras F. Rioprostil and ranitidine in the prevention of duodenal ulcer relapse. Scand J Gastroenterol 1989, 24(suppl 164), 146-151 One hundred and ninety duodenal ulcer patients who had relief of pain and endo-scopically proven ulcer healing after a short treatment period are allocated at random to double-blind maintenance treatment with a synthetic dehydroprostaglandin-E1, rioprostil, 300 μg, or ranitidine, 150 mg, at bedtime for 6 months. Patients are monitored every two months and examined by endoscopy after six months of treatment, or more often if warranted. The cumulative relapse rate in the rioprostil group at six months is 32% (25/78) us. 28% (20/72) in the ranitidine group. This difference is not significant. The percentage of side effects observed is 17% in the rioprostil group us. 5% in the ranitidine group, but discontinuation of treatment is observed with the same frequency in the two groups.